Astellas Pharma Inc.

BMV:4503 N Stock Report

Market Cap: Mex$303.4b

Astellas Pharma Past Earnings Performance

Past criteria checks 0/6

Astellas Pharma's earnings have been declining at an average annual rate of -24.7%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 3.7% per year. Astellas Pharma's return on equity is 0.3%, and it has net margins of 0.3%.

Key information

-24.7%

Earnings growth rate

-23.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate3.7%
Return on equity0.3%
Net Margin0.3%
Next Earnings Update25 Apr 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Astellas Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:4503 N Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,543,3244,198706,256286,410
30 Sep 231,523,57238,090669,778278,898
30 Jun 231,511,818107,031645,058266,713
31 Mar 231,518,61998,714630,272276,128
31 Dec 221,468,235136,430613,397274,414
30 Sep 221,406,682148,911586,290266,127
30 Jun 221,351,811118,211565,127261,704
31 Mar 221,296,163124,086548,840246,010
31 Dec 211,300,914120,167547,692233,316
30 Sep 211,285,714119,360532,687231,849
30 Jun 211,268,702100,863520,649225,514
31 Mar 211,249,528120,589504,316224,489
31 Dec 201,253,215138,307508,764233,293
30 Sep 201,265,853139,722515,363230,952
30 Jun 201,273,678187,306502,601228,007
31 Mar 201,300,843195,411499,295224,226
31 Dec 191,289,855220,751488,054218,477
30 Sep 191,309,722246,925484,800214,090
30 Jun 191,311,397226,224494,845210,057
31 Mar 191,306,348222,265490,263208,682
31 Dec 181,305,901213,600484,099209,117
30 Sep 181,307,658186,429481,546212,867
30 Jun 181,306,830176,770478,883216,436
31 Mar 181,300,316164,679478,330220,781
31 Dec 171,305,521182,515484,126221,463
30 Sep 171,299,746185,754478,249215,938
30 Jun 171,296,484194,556471,227213,584
31 Mar 171,311,665218,701470,777208,129
31 Dec 161,312,627207,940474,335208,958
30 Sep 161,336,878205,818481,460213,295
30 Jun 161,366,799215,678493,582220,707
31 Mar 161,372,706193,687500,359225,665
31 Dec 151,360,153185,659497,984223,590
30 Sep 151,340,307168,805490,493221,608
30 Jun 151,295,761144,617474,276214,931
31 Mar 151,247,259135,856452,522206,594
31 Dec 141,205,276124,154251,755339,460
30 Sep 141,177,660112,663296,063288,487
30 Jun 141,159,218104,614343,246239,103
31 Mar 141,139,90990,874397,018191,460
31 Dec 131,137,82479,679433,675181,955
30 Sep 131,085,48173,641410,183181,955
30 Jun 131,038,22769,483561,3920

Quality Earnings: 4503 N has a large one-off loss of ¥85.2B impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: 4503 N's current net profit margins (0.3%) are lower than last year (9.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4503 N's earnings have declined by 24.7% per year over the past 5 years.

Accelerating Growth: 4503 N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4503 N had negative earnings growth (-96.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7.8%).

Return on Equity

High ROE: 4503 N's Return on Equity (0.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y